ReP USP - Resultado da busca

Artigo de periodico
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial (2019)
Ray, Kausik K; Colhoun, Helen M; Szarek, Michael; Baccara-dinet, Marie; Bhatt, Deepak L; Bittner, Vera A; Budaj, Andrzej J; Diaz, Rafael; Goodman, Shaun G; Nicolau, José Carlos
Source: Lancet diabetes & endocrinology. Unidade: FM
Subjects: SÍNDROME CORONARIANA AGUDA, DIABETES MELLITUS, ANTICORPOS MONOCLONAIS, DOENÇAS CARDIOVASCULARES, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RAY, Kausik K et al. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet diabetes & endocrinology, v. 7, n. 8, p. 618-628, 2019Tradução . . Disponível em: https://doi.org/10.1016/S2213-8587(19)30158-5. Acesso em: 07 nov. 2024.
APA
Ray, K. K., Colhoun, H. M., Szarek, M., Baccara-dinet, M., Bhatt, D. L., Bittner, V. A., et al. (2019). Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet diabetes & endocrinology, 7( 8), 618-628. doi:10.1016/S2213-8587(19)30158-5
NLM
Ray KK, Colhoun HM, Szarek M, Baccara-dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Nicolau JC. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial [Internet]. Lancet diabetes & endocrinology. 2019 ; 7( 8): 618-628.[citado 2024 nov. 07 ] Available from: https://doi.org/10.1016/S2213-8587(19)30158-5
Vancouver
Ray KK, Colhoun HM, Szarek M, Baccara-dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Nicolau JC. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial [Internet]. Lancet diabetes & endocrinology. 2019 ; 7( 8): 618-628.[citado 2024 nov. 07 ] Available from: https://doi.org/10.1016/S2213-8587(19)30158-5
Artigo de periodico
Long-term survival following multivessel revascularization in patients with diabetes The FREEDOM Follow-On Study: the FREEDOM follow-on study (2019)
Farkouh, Michael E; Domanski, Michael; Dangas, George D; Godoy, Lucas C; Mack, Michael J; Siami, Flora S; Hamza, Taye H; Shah, Binita; Stefanini, Giulio G; Sidhu, Mandeep S; Hueb, Whady Armindo
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: REVASCULARIZAÇÃO MIOCÁRDICA, SOBREVIDA, DIABETES MELLITUS, CORONARIOPATIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FARKOUH, Michael E et al. Long-term survival following multivessel revascularization in patients with diabetes The FREEDOM Follow-On Study: the FREEDOM follow-on study. Journal of the american college of cardiology, v. 73, n. 6, p. 629-638, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2018.11.001. Acesso em: 07 nov. 2024.
APA
Farkouh, M. E., Domanski, M., Dangas, G. D., Godoy, L. C., Mack, M. J., Siami, F. S., et al. (2019). Long-term survival following multivessel revascularization in patients with diabetes The FREEDOM Follow-On Study: the FREEDOM follow-on study. Journal of the american college of cardiology, 73( 6), 629-638. doi:10.1016/j.jacc.2018.11.001
NLM
Farkouh ME, Domanski M, Dangas GD, Godoy LC, Mack MJ, Siami FS, Hamza TH, Shah B, Stefanini GG, Sidhu MS, Hueb WA. Long-term survival following multivessel revascularization in patients with diabetes The FREEDOM Follow-On Study: the FREEDOM follow-on study [Internet]. Journal of the american college of cardiology. 2019 ; 73( 6): 629-638.[citado 2024 nov. 07 ] Available from: https://doi.org/10.1016/j.jacc.2018.11.001
Vancouver
Farkouh ME, Domanski M, Dangas GD, Godoy LC, Mack MJ, Siami FS, Hamza TH, Shah B, Stefanini GG, Sidhu MS, Hueb WA. Long-term survival following multivessel revascularization in patients with diabetes The FREEDOM Follow-On Study: the FREEDOM follow-on study [Internet]. Journal of the american college of cardiology. 2019 ; 73( 6): 629-638.[citado 2024 nov. 07 ] Available from: https://doi.org/10.1016/j.jacc.2018.11.001
Artigo de periodico
Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes (2018)
Everett, Brendan M.; Nicolau, Jose C.; DONATH, Marc Y.; PRADHAN, Aruna D.; THUREN, Tom; PAIS, Prem; GLYNN, Robert J; LIBBY, Peter; RIDKER, Paul M.
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: ANTI-INFLAMATÓRIOS, DOENÇAS CARDIOVASCULARES, DIABETES MELLITUS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
EVERETT, Brendan M. et al. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. Journal of the american college of cardiology, v. 71, n. 21, p. 2392-2401, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2018.03.002. Acesso em: 07 nov. 2024.
APA
Everett, B. M., Nicolau, J. C., DONATH, M. Y., PRADHAN, A. D., THUREN, T., PAIS, P., et al. (2018). Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. Journal of the american college of cardiology, 71( 21), 2392-2401. doi:10.1016/j.jacc.2018.03.002
NLM
Everett BM, Nicolau JC, DONATH MY, PRADHAN AD, THUREN T, PAIS P, GLYNN RJ, LIBBY P, RIDKER PM. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes [Internet]. Journal of the american college of cardiology. 2018 ; 71( 21): 2392-2401.[citado 2024 nov. 07 ] Available from: https://doi.org/10.1016/j.jacc.2018.03.002
Vancouver
Everett BM, Nicolau JC, DONATH MY, PRADHAN AD, THUREN T, PAIS P, GLYNN RJ, LIBBY P, RIDKER PM. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes [Internet]. Journal of the american college of cardiology. 2018 ; 71( 21): 2392-2401.[citado 2024 nov. 07 ] Available from: https://doi.org/10.1016/j.jacc.2018.03.002
Artigo de periodico
Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) (2018)
Giugliano, Robert P.; Nicolau, Jose Carlos
Source: Circulation. Unidade: FM
Subjects: DIABETES MELLITUS, DOENÇAS CARDIOVASCULARES, FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GIUGLIANO, Robert P. e NICOLAU, Jose Carlos. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation, v. 137, n. 15, p. 1571-0, 2018Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.117.030950. Acesso em: 07 nov. 2024.
APA
Giugliano, R. P., & Nicolau, J. C. (2018). Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation, 137( 15), 1571-0. doi:10.1161/CIRCULATIONAHA.117.030950
NLM
Giugliano RP, Nicolau JC. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) [Internet]. Circulation. 2018 ; 137( 15): 1571-0.[citado 2024 nov. 07 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.117.030950
Vancouver
Giugliano RP, Nicolau JC. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) [Internet]. Circulation. 2018 ; 137( 15): 1571-0.[citado 2024 nov. 07 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.117.030950
Artigo de periodico
ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD (2017)
Charytan, David M.; Burdmann, Emmanuel de Almeida
Source: American journal of kidney diseases. Unidade: FM
Subjects: FALÊNCIA RENAL CRÔNICA, DOENÇAS CARDIOVASCULARES, DIABETES MELLITUS, INFARTO DO MIOCÁRDIO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CHARYTAN, David M. e BURDMANN, Emmanuel de Almeida. ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD. American journal of kidney diseases, v. 70, n. 4, p. 522-531, 2017Tradução . . Disponível em: http://observatorio.fm.usp.br/handle/OPI/21785. Acesso em: 07 nov. 2024.
APA
Charytan, D. M., & Burdmann, E. de A. (2017). ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD. American journal of kidney diseases, 70( 4), 522-531. doi:10.1053/j.ajkd.2017.04.018
NLM
Charytan DM, Burdmann E de A. ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD [Internet]. American journal of kidney diseases. 2017 ; 70( 4): 522-531.[citado 2024 nov. 07 ] Available from: http://observatorio.fm.usp.br/handle/OPI/21785
Vancouver
Charytan DM, Burdmann E de A. ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD [Internet]. American journal of kidney diseases. 2017 ; 70( 4): 522-531.[citado 2024 nov. 07 ] Available from: http://observatorio.fm.usp.br/handle/OPI/21785

USP Schools

ReP

Filtros

Authors

Subjects

Funding Agencies